Investigating subregional PD-L1 expression within primary tumors to predict clinical outcomes in advanced NSCLC patients who received ICB-based therapy
PD-L1 from the deep subregion is a more solid predictive biomarker of both short- and long-time efficacies of ICB-based therapy, and optimizing the assessment of spatial heterogeneity provides a new perspective for clinicians to screen advanced NSCLC patients who can benefit from ICB-based therapy.
Authors
- Ziwen Zhu (ORCID: https://orcid.org/0000-0002-6681-9153)
- Jingyu Mao
- Cheng Chen (ORCID: https://orcid.org/0000-0002-9583-7991)
- Meiqin Su
- Danhong Zhou (ORCID: https://orcid.org/0000-0003-3933-5185)
Institutions
- Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-17
- DOI
- https://doi.org/10.3389/fonc.2025.1497279
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Suzhou City
- National Natural Science Foundation of China